264 related articles for article (PubMed ID: 11520606)
1. Differential osteopontin expression in lung cancer.
Zhang J; Takahashi K; Takahashi F; Shimizu K; Ohshita F; Kameda Y; Maeda K; Nishio K; Fukuchi Y
Cancer Lett; 2001 Oct; 171(2):215-22. PubMed ID: 11520606
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of p63 expression in lung cancer by use of complementary DNA and tissue microarray].
Yu YW; Garber ME; Schlüns K; Pacyna-Gengelbach M; Petersen I
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):324-7. PubMed ID: 15363316
[TBL] [Abstract][Full Text] [Related]
3. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin expression in lung cancer.
Chambers AF; Wilson SM; Kerkvliet N; O'Malley FP; Harris JF; Casson AG
Lung Cancer; 1996 Nov; 15(3):311-23. PubMed ID: 8959677
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.
Zhao B; Sun T; Meng F; Qu A; Li C; Shen H; Jin Y; Li W
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1061-70. PubMed ID: 21207061
[TBL] [Abstract][Full Text] [Related]
8. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer.
Casson AG; Wilson SM; McCart JA; O'Malley FP; Ozcelik H; Tsao MS; Chambers AF
Int J Cancer; 1997 Sep; 72(5):739-45. PubMed ID: 9311587
[TBL] [Abstract][Full Text] [Related]
9. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Cohen AJ; Bunn PA; Franklin W; Magill-Solc C; Hartmann C; Helfrich B; Gilman L; Folkvord J; Helm K; Miller YE
Cancer Res; 1996 Feb; 56(4):831-9. PubMed ID: 8631021
[TBL] [Abstract][Full Text] [Related]
10. Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
Suzuki M; Shigematsu H; Shames DS; Sunaga N; Takahashi T; Shivapurkar N; Iizasa T; Minna JD; Fujisawa T; Gazdar AF
Ann Surg Oncol; 2007 Apr; 14(4):1397-404. PubMed ID: 17195088
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer.
Nishio H; Nakamura S; Horai T; Ikegami H; Matsuda M
Cancer; 1992 Mar; 69(5):1130-6. PubMed ID: 1310887
[TBL] [Abstract][Full Text] [Related]
12. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.
Oates AJ; Barraclough R; Rudland PS
Oncogene; 1996 Jul; 13(1):97-104. PubMed ID: 8700559
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma.
Štemberger C; Matušan-Ilijaš K; Avirović M; Bulat-Kardum L; Ivančić A; Jonjić N; Lučin K
Acta Histochem; 2014 Jan; 116(1):222-9. PubMed ID: 23992637
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.
Schneider S; Yochim J; Brabender J; Uchida K; Danenberg KD; Metzger R; Schneider PM; Salonga D; Hölscher AH; Danenberg PV
Clin Cancer Res; 2004 Mar; 10(5):1588-96. PubMed ID: 15014008
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity.
Devoll RE; Li W; Woods KV; Pinero GJ; Butler WT; Farach-Carson MC; Happonen RP
J Oral Pathol Med; 1999 Mar; 28(3):97-101. PubMed ID: 10069535
[TBL] [Abstract][Full Text] [Related]
16. Cell-substratum interactions mediate oncogene-induced phenotype of lung cancer cells.
Barr LF; Campbell SE; Penno MB; Ball DW; Baylin SB
Cell Growth Differ; 1996 Sep; 7(9):1149-56. PubMed ID: 8877096
[TBL] [Abstract][Full Text] [Related]
17. Cloning of hamster osteopontin and expression distribution in normal tissues and experimentally induced oral squamous-cell carcinoma.
Jin H; Valverde P; Chen J
Arch Oral Biol; 2006 Mar; 51(3):236-45. PubMed ID: 16095557
[TBL] [Abstract][Full Text] [Related]
18. [Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof].
Gui SY; Li HH; Zuo L; Zhou Q; Wu Q; Wang Y
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3219-23. PubMed ID: 18399118
[TBL] [Abstract][Full Text] [Related]
19. The small GTPase RhoA has greater expression in small cell lung carcinoma than in non-small cell lung carcinoma and contributes to their unique morphologies.
Varker KA; Phelps SH; King MM; Williams CL
Int J Oncol; 2003 Mar; 22(3):671-81. PubMed ID: 12579323
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
